195P REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 33; p. S217
Main Authors Singer, C.F., Egle, D., Greil, R., Petru, E., Ohler, L., Balic, M., Tinchon, C., Pfeiler, G., Marhold, M., Brunner, C., Haider, K., Galid, A., Pluschnig, U., Haslbauer, F., Hubalek, M., Redl, A., Flatschacher, J., Uthman, S., Mraz, B., Bartsch, R.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.05.2022
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2022.03.214